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occurred in the IMI group but not in the AMI group. Improvements in LVEF and MR were
similar in both groups. CONCLUSION: Infarct location determines the extent of reverse
LV remodeling in HF pts treated with CRT independent of baseline LV volume and func-
tion. 
* p<0.05 AMI vs IMI
† p<0.05 within group changes, baseline to 6-months
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872-2 Upgrade From Standard Right Sided Pacing to Cardiac 
Resynchronization Therapy Shows Clinical Benefit as in 
De Novo Implantation
Salpy V. Pamboukian, Imran Nisar, Sheetal Patel, Liping Gu, Mary McLeod, Stephanie 
Dunlap, Richard Trohman, Maria Rosa Costanzo, Alain Heroux, University of Alabama at 
Birmingham, Birmingham, AL, Rush Presbyterian St. Luke's Medical Center, Chicago, IL
Background: Cardiac resynchronization therapy (CRT) produces clinical benefit in heart
failure (HF) patients (pts) with intraventricular conduction delay. Previous studies
excluded pts who already had a pacing device. In this study, pts with denovo (DN) CRT
were compared to those undergoing upgrade (UP) to CRT from standard pacing.
Methods: Data from the Rush Heart Failure Database was collected including demo-
graphics, cause of HF, NYHA class, echo data (left ventricular ejection fraction LVEF, LV
end diastolic dimension EDD, mitral regurgitation MR, tricuspid regurgitation TR), ECG
intervals, drugs, hospitalizations (hosp), length of stay (LOS), procedure complications
and mortality. Statistics were performed using t test, Fisher's exact test, Wilcoxon test.
Results: Twenty eight pts had DN implant (19 male, 13 ischemic, LVEF 20%, LVEDD
72mm), 21 pts had UP (15 male, 13 ischemic, LVEF 24%, LVEDD 73mm). Age was 61+9
yrs in DN versus (vs) 67+10 in UP (p<0.01). PR interval was 188+34ms in DN vs
156+57ms in UP. QRS duration was 152+21ms in DN vs 181+35ms in UP (p<0.01). In
the DN, LVEDD decreased by 4+2mm after CRT (p=0.04). In the UP, MR was less after
CRT(p=0.02). Both groups had improved NYHA class immediately after CRT (p=0.02). In
DN group this was still seen at 6 and 12 months (P<0.01). No difference was seen in the
number of hosp in the groups 6 months before and after CRT. There was a trend to
shorter LOS in the in the DN pts after CRT, -5+ 2.5days(p=0.07). Dose of metoprolol suc-
cinate was 62+17mg at baseline in DN pts but increased by 53+19mg after CRT(p=0.01).
Carvedilol dose was unchanged. No difference in beta blocker dose after CRT was seen
in the UP pts. There were no differences in CRT related complications. There were 3
deaths in UP, 4 in DN group.
Conclusion: HF pts with standard pacing benefit from upgrade to CRT with improved
NYHA class and decreased MR, without increased procedure related complications.
CRT allows for uptitration of beta blockers in DN implants.
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872-3 Reverse Remodeling After Cardiac Resynchronization 
Therapy and Analysis of Effect in Heart Failure Patients 
With or Without an Indication for Implantable 
Cardioverter Defibrillator
Martin G. St. John Sutton, Ted Plappert, Kathryn E. Hilpisch, Edward Chinchoy, 
University of Pennsylvania Medical Center, Philadelphia, PA, Medtronic, Inc, Minneapolis, 
MN
Evidence of reverse remodeling with CRT in moderate to severe heart failure (HF)
patients (pts) with ventricular dysynchrony has been reported in several trials. An analy-
sis was done to compare the results of a CRT versus a CRT+ICD trial. METHODS: We
compared the magnitude of remodeling of two separate CRT trials differentiated by pts
with and without an indication for an ICD. The MIRACLE and MIRACLE ICD trials
enrolled HF pts (NYHA III/IV, QRS>130ms, LVEDD >55mm and EF<35%) and implanted
them with an InSync (atrial synchronous biventricular pacer) or an InSync ICD system,
respectively. In all pts AV delay was echocardiographically optimized by maximizing left
transmitral filling without truncating the A wave. Patients were randomized to no pacing
(control) or to treatment (CRT or CRT+ICD). Peak VO2 consumption (pVO2), 6-minute
hall walk distance (6’HW) and Quality of life (QoL) were compared. Doppler echocardio-
grams were recorded in pts at baseline and 6 months, and analyzed by a core laboratory.
LV end diastolic volume (LVEDV), LV end systolic volume (LVESV), LV ejection fraction
(LVEF), Deceleration time (DT), and mitral regurgitation color flow jet area (MR) were
obtained. Only treatment patients with paired baseline and 6 mos data were used.
RESULTS: See table. CONCLUSIONS: The magnitude of clinical improvements and
reverse remodeling quantified using echocardiographic indices was similarly evident in
both trials regardless of indication or placement of an ICD. *p<0.05 between baseline and
6 months. 
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872-4 Benefit of Biventricular Pacing in Subsets of Patients 
With Heart Failure
Kenneth Ng, Navin Kedia, Randall Starling, Bruce Wilkoff, Pat Tchou, David Martin, 
Richard Grimm, Cleveland Clinic Foundation, Cleveland, OH
Background
Extending the current indications for cardiac resynchronization therapy (CRT) to patients
with NYHA Class II symptoms, RV pacing or QRS < 150ms has been proposed however
no data has yet been reported to support this recommendation.
Methods
One-hundred and forty-four consecutive heart failure patients underwent CRT from Janu-
ary 1999 to January 2002. Clinical parameters of NYHA Class, QRS duration, LVEF, LV
end-systolic (LVESD) and end-diastolic (LVEDD) dimensions were monitored at baseline
and end of follow-up with a mean of 330 ± 220 days.
Results
At baseline, 20 patients, 88 patients and 36 patients were in NYHA Class II, Class III and
Class IV respectively, 34 patients with right ventricle pacing, and 29 patients with a QRS
duration <150ms. After CRT, the patients who were in NYHA Class II had significant
improvement in LVEF and LV dimensions. Patients with RV pacing had significant
improvement in NYHA Class, QRS duration, LVEF and LV dimensions. The patients with
QRS duration < 150ms had significant improvement in NYHA class and a significant
increase in the QRS duration.(Table I)
Conclusion
Non-conventional candidates for CRT may derive significant structural and functional
benefit with CRT and should be analyzed in future clinical trials. 
* denotes difference is significant, p<0.05
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872-5 Incidence of Diastolic Dyssynchrony in Dilated 
Cardiomyopathy and Effects of Biventricular Pacing
Christophe Jego, Iris Schuster, Christine Medail, Jean Lefevre, Frederic Franceschi, 
Jean-Marie Vailloud, Ange Ferracci, Jean-Claude DeHaro, Pierre Djiane, Gilbert H. 
Habib, La Timone Hospital, Marseille, France
Background. Resynchronization is an accepted treatment of dilated cardiomyopathy
(DCM). Its benefit has been related to the correction of systolic (S) dyssynchrony (DYS)
either interventricular (Inter) or intraventricular (Intra). However, little is known about dias-
tolic (D) DYS and the effects of biV pacing on it
Objectives: 
1 - to compare the respective occurrence of D and S DYS in pts with DCM and LBBB.
2 – to assess changes in both D and S delays under Biv pacing
Methods. 37 pts with DCM and wide QRS were studied by Tissue Doppler Imaging (TDI)
before and immediately after biV pacing. S and D parameters were measured using
delays between onset of QRS and onset of the TDI velocity curves. The septal and lateral
walls of the left ventricle were used to assess Intra DYS. Similar measurements between
lateral free walls of right and left ventricles were used to assess Inter DYS.
AMI IMI
Baseline
Mean ± Std 
6mo. Median 
Paired 
Difference, 
(95% C.I.)
Baseline
Mean ± Std
6mo. Median Paired 
Difference,
(95% C.I.)
LVEDV, cm3 297.6 ±97.4 
(n=48)
1.6 (-23.4, 20.7) 307.8±94.6 
(n=28)
-43.2 (-69.0, 0.4)†*
LVESV, cm3 229.6±89.5 
(n=48)
-5.4 (-18.6, 3.7) 235.1±82.3 
(n=28)
-24.1 (-66.6, -11.3)†*
LV EF, % 24.1±6.2 (n=48) 2.3 (0.8, 3.9)† 24.6±6.8 (n=28) 3.2 (0.2, 4.5)†
MR Jet 
Area, cm2
9.35±4.88 (n=36) -4.2 (-5.8, -2.6)† 8.20±5.32 (n=17) -4.0 (-5.9, 2.3)†
mean ± std MIRACLE
(n=196)
MIRACLE ICD
(n=165)
Baseline 6 mo Baseline 6 mo
LVEDV (ml) 302±107 266±109* 318±95 299±101*
LVESV (ml) 233±98 195±99* 245±88 224±94*
LVEF (%) 24.2±6.8 29.2±9.0* 24.2±6.5 27.3±8.9*
MR (cm2) 7.4±5.9 4.3±4.4* 7.7±6.0 6.4±5.4*
DT (ms) 199±84 236±108* 197±80 215±78*
pVO2 14.3±3.5 15.4±4.1* 13.5±3.5 14.3±3.7*
6’ HW (m) 310±83 335±125* 250±127 338±106*
QOL 59±20 39±24* 55±23 37±24*
Patient 
Subgroups
NYHA Class II NYHA Class III/
IV
RV Pacing QRS duration < 
150ms
Clinical 
Variables
Pre-
CRT
Post-
CRT
Pre-
CRT
Post-
CRT
Pre-
CRT
Post-
CRT
Pre-
CRT
Post-
CRT
NYHA Class 2 1.75 3.1* 2.5* 3.1* 2.5* 2.9* 2.5*
QRS Duration 
(ms)
171 159 174* 164* 195* 165* 137* 155*
LVEF (%) 17.9* 27.6* 18.9* 23* 18.1* 22.2* 22 22
LVEDD (cm) 6.6* 6.1* 6.8* 6.5* 6.4* 6.1* 6.6 6.5
LVESD (cm) 5.5* 4.8* 5.7* 5.3* 5.4* 5.1* 5.5 5.3
